- New NICE recommendations demonstrate significant benefits of
hybrid closed loop systems (HCL) – a form of automated insulin
delivery with minimal user interaction – for people with
diabetes3.
- HCL systems, powered by Dexcom CGM, can significantly improve a
user’s time in their target glucose range and lower their HbA1c
levels4-6.
- New survey data from Dexcom suggests almost half (45%) of
people with diabetes don’t understand what a Hybrid Closed Loop
System (HCL) is or how HCL could benefit them1-2.
DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time
continuous glucose monitoring (rtCGM) for people with diabetes,
announced today new market research which found 79% of people
struggle to keep their glucose levels in range, and that almost
half (45%) don’t understand what a Hybrid Closed Loop System (HCL)
is or how HCL could benefit them1-2. Findings also showed that 99%
of healthcare providers expect the NICE TA for HCL systems will
somewhat or significantly help change the lives of people living
with type 1 diabetes for the better1-2.
Dexcom’s research follows the new Technology Appraisal (TA) from
NICE which provides detailed guidance for hybrid closed loop
systems usage. The new TA impacts an eligible population of over
150,000 people living with Type 1 diabetes in England, providing
access to HCL systems3. Those eligible include people living with
type 1 diabetes who are under the age of 18 or those who are over
18 with either an HbA1c of 7.5% or who are experiencing disabling
hypoglycaemia, the TA also impacts women who are pregnant or
planning a pregnancy, and people already using an insulin
pump3.
Sometimes known as an ‘artificial pancreas’, an HCL system works
by linking an insulin pump and continuous glucose monitor (CGM)
with a computer algorithm that can calculate the amount of insulin
someone needs based on their blood glucose readings.
“It's a cause for celebration that hybrid closed loop systems
are now a possibility for around 150,000 people with type 1
diabetes” says Partha Kar, National Specialty Advisor, Diabetes
with NHS England. “This guidance would not have been possible
without the support of our industry partners investing in new
innovations and advancing technology for diabetes management. Today
we are one step closer to providing access to life changing
technology for more people with diabetes.”
Karen Baxter, VP for UK Ireland Benelux Spain and France for
Dexcom comments: “It is clear from our research1-2 that so many
more people could benefit from HCL. Every single person (100%)
surveyed with type 1 diabetes said that being on an HCL system has
reduced the burden of managing their diabetes and 98% of healthcare
practitioners say they would want all people with type 1 diabetes
to have access to HCL. The newly announced TA from NICE3 is a great
advancement in access to diabetes technology.
“As such, to support healthcare professionals with their
understanding of the benefits of HCL systems for patients with
diabetes, Dexcom has worked with the clinical experts at the
Diabetes Technology Network (DTN) to launch a series of education
modules encompassing everything they need to know about the
technology, we are excited to play a key role in widening access to
HCL as a result.”
Celebrity Dexcom Warrior and HCL user, actor Jeremy
Irvine† comments: “I can honestly say using the Dexcom
G6 continuous glucose monitoring device to power my HCL system has
changed my life. I can’t imagine going back to finger pricks* and
blood glucose monitoring, and I certainly couldn’t do the intense
filming I’ve been doing without my HCL system.”
Dexcom is the most connected continuous glucose monitoring (CGM)
brand in the world7, it is backed by over 28 studies8‡§, has
powered HCL systems for over one million years of cumulative
patient use7, and is a critical and essential component of an HCL
system. HCL systems powered by Dexcom real-time CGM have been
proven to significantly improve outcomes – giving people with
diabetes more confidence in their diabetes management4-6, 8-11.
In fact, a Dexcom sponsored study, ‘AiDAPT’, published in the
New England Journal of Medicine last month, showed hybrid
closed-loop therapy significantly improved maternal glycemic
control during pregnancy complicated by type 1 diabetes11. The
study, which focused on 124 pregnant women in nine sites across the
UK and used the Dexcom G6 as part of the HCL system, further
highlights the efficacy of utilising an HCL system to help manage
glucose levels.
Dexcom will further strengthen its position as the world’s most
connected CGM system when the Dexcom G7 CGM system launches with
the Tandem t:slim X2 insulin pump. This news follows the recent
launch of the Omnipod 5 Automated Insulin Delivery System connected
to Dexcom G6 in the UK and Germany.
Methodology
Patient Survey
The research was commissioned by Dexcom and conducted by
Censuswide with 500 people with type 1 diabetes including 50 people
using a hybrid closed loop system to manage their diabetes between
09.10.2023 - 16.10.2023. Censuswide abide by and employ members of
the Market Research Society which is based on the ESOMAR principles
and are members of The British Polling Council.
Healthcare Practitioner
Survey
The research was conducted by Censuswide with 251 UK healthcare
professionals (aged 18+) involved in the care of people with T1
diabetes between 10.10.2023 - 18.10.2023. Censuswide abide by and
employ members of the Market Research Society which is based on the
ESOMAR principles and are members of The British Polling
Council.
About DexCom, Inc.
DexCom, Inc. empowers people to take control of diabetes through
innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, California, and with operations across
Europe, Dexcom has emerged as a leader of diabetes care technology.
By listening to the needs of users, caregivers, and providers,
Dexcom simplifies and improves diabetes management around the
world. For more information about Dexcom CGM, visit
https://www.dexcom.com/en-gb.
Notes for Editors
The Dexcom CGM G6 currently connects to the following insulin
pumps to create a hybrid closed loop system in the UK:
- Tandem t:slimX2 insulin pump and Tandem Control-IQ control
algorithm
- Omnipod 5 automated insulin delivery system (Insulet) and
Omnipod tubeless insulin pod (Insulet).
- Ypsomed mylife YpsoPump with Camdiab CamAPS FX
To access Dexcom’s series of Hybrid Closed Loop education
modules, which were developed in partnership with the Diabetes
Technology Network, please register here:
https://uk-educationhub.dexcom.com/users/sign_up
*Finger pricks required for diabetes treatment decisions if
symptoms or expectations do not match readings.
†Jeremy Irvine is a sponsored spokesperson of Dexcom.
‡Study also includes studies published after the inclusion
criteria in the review.
§Dexcom data on file, 2023.
1. Dexcom and Censuswide online survey of people living with
Type 1 diabetes, conducted in the UK, H2 2023, N=500, including at
least 50 people using a hybrid closed loop system to manage their
diabetes. 2. Dexcom and Censuswide online survey of healthcare
practitioners involved in the care of people with Type 1 diabetes,
conducted in the UK, H2 2023, N=251, including at least 50 people
in secondary healthcare such as Diabetes Specialist Nurses and
Consultant Endocrinologists. 3. National Institute for Health and
Care Excellence
https://www.nice.org.uk/guidance/gid-ta10845/documents/final-appraisal-determination-document
4. Brown SA, et al. N Engl J Med. 2019;381(18):1707-1717. 5. Breton
MD, et al. N Engl J Med. 2020;383(9):836-845. 6. Brown SA, et al.
Diabetes Care. 2021;44(7):1630-1640. 7. Data on file 2023. 8.
Peacock S, et al. Diabetes Ther. 2023;14(5):839-855. 9. Sherr JL,
et al. Diabetes Care. 2022;45(12):3058-3074. 10. Farrington C.
Diabet Med 2018;35:436–449. 11. Lee T., et al. NEJM. 2023. Oct 5.
doi: 10.1056/ NEJMoa2303911.
© 2023 Dexcom, Inc. Dexcom, Dexcom ONE, Dexcom G6 and Dexcom G7
are registered trademarks of DexCom, Inc. in the U.S., and may be
registered in other countries. All rights reserved.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108723653/en/
Allison for Dexcom dexcomUK@allisonworldwide.com
Grafico Azioni DexCom (NASDAQ:DXCM)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni DexCom (NASDAQ:DXCM)
Storico
Da Mag 2023 a Mag 2024